Price of adagrasib in 2024, how much does a box of generic drugs cost?

Adagrasib, also known asKrazati, is an innovative drug that belongs to the RAS GTPase family of inhibitors. This property allows it to effectively target a specific genetic mutation - the KRAS G12C mutation. KRAS G12C mutation plays a key role in a variety of cancers, especially in non-small cell lung cancer, where the presence of this mutation often means disease progression and increased difficulty in treatment.

Adagrasiib is available as an oral tablet. It is usually taken twice a day with or without food for as long as your doctor recommends treatment. Take adagrasiib at approximately the same time each day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any parts you don't understand. Take adagrasibu exactly as directed. Do not take more or less than prescribed by your doctor.

Adagrasib, with its precise therapeutic mechanism, brings new treatment opportunities to patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer. These patients have often undergone one or more rounds of systemic therapy and have an urgent need for new treatment strategies. As a monotherapy, adagrasib can exert significant efficacy in such situations, helping patients prolong their survival and improve their quality of life.

What is more worth mentioning is that adagrasib shows a more powerful therapeutic effect when used in combination with cetuximab. As a targeted therapy drug, the combined use of cetuximab and adagrasib can produce a synergistic effect and further enhance the therapeutic effect on KRAS G12C mutant cancers. This combination treatment option offers new hope for patients who have not responded well to traditional treatments.

The development and application of adagrasib not only reflects modern medicine's pursuit of precise treatment, but also reflects the continued innovation and efforts of scientists in the field of anti-cancer drug research and development. With the deepening of research and the expansion of clinical applications, we have reason to believe that adagrasib will bring good news to more cancer patients in the future.

Adagrasib is not currently on the market in China, so it cannot be included in domestic medical insurance reimbursement items. It is understood that the first generic drug of adagrasibu has recently appeared on the Lao market. This innovative move has brought new hope to patient families around the world who have given up treatment due to the high price of original drugs. The launch of the Lao version of the generic version of adagrasibu has successfully broken the price monopoly of the original drug and significantly reduced the cost of treatment, from the original 200,000 yuan per month to only 8,000 to 9,000 yuan per month. For patients who have more questions about adagrasib, it is recommended to consult regular overseas medical service institutions.